Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome

Abstract

Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof-of-principle trials for some drug targets.